120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
为中国医院药品目录决策提供依据：GLP-1 受体激动剂的多准则价值框架
Authors Jiang Y, Qin D , Lin S, Xu X, Wang H
Received 5 September 2025
Accepted for publication 26 January 2026
Published 21 February 2026 Volume 2026:19 564791
DOI https://doi.org/10.2147/RMHP.S564791
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Gulsum Kaya
Yuancheng Jiang,1 Dan Qin,2 Sitong Lin,1 Xingxing Xu,1 Haiyin Wang3
1Department of Pharmacy Management, College of International Pharmaceutical Business School, China Pharmaceutical University, Nanjing, People’s Republic of China; 2Department of Pharmacy, School of Pharmaceutical Sciences and Yunnan Provincial Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, People’s Republic of China; 3Health Technology Assessment Research Department, Shanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai, People’s Republic of China
Correspondence: Haiyin Wang, Health Technology Assessment Research Department, Shanghai Health Development Research Center (Shanghai Medical information Center), Shanghai, People’s Republic of China, Email wanghaiyin@shdrc.org
Purpose: GLP-1 receptor agonists have attracted increasing attention due to their dual efficacy in glycemic control and weight reduction. Although several GLP-1 receptor agonists have been included in China’s National Reimbursement Drug List, their actual adoption at the hospital level still faces multiple challenges. A well-structured evaluation framework is urgently needed to facilitate their integration into hospital formularies. This study aims to develop a clinically comprehensive evaluation system for GLP-1 receptor agonists in public hospital drug selection, based on multicriteria decision analysis (MCDA). The goal is to provide a systematic and quantifiable tool to support the rational selection and implementation of GLP-1RAs in public hospitals, thereby enhancing the scientific basis of hospital formulary decisions.
Patients and Methods: The study integrates the Delphi method and multi-criteria decision analysis (MCDA), utilizing literature review, expert consultations, and questionnaire surveys to select and assign weights to evaluation indicators.
Results: A three-tier evaluation system was established, comprising four primary indicators, eight secondary indicators, and seventeen tertiary indicators. Among them, “Clinical Value” had the highest weight (0.5373), followed by “Hospital Admission Demand” (0.1924) and “Hospital Management” (0.1379), while “Economic Value” had the lowest weight (0.1324). At the tertiary level, “Cost-Effectiveness Advantage”, “Glycosylated Hemoglobin”, “Cardiovascular, Hepatic, and Renal Benefits”, “Addressing Unmet Clinical Needs”, and “Hypoglycemia Incidence” contributed most to decision-making.
Conclusion: This study fills the gap in clinical evaluation research on GLP-1RA drugs in China. The proposed evaluation system provides scientific support for hospital pharmaceutical management, medical insurance inclusion, and drug procurement, promoting value-based hospital drug selection strategies.
Keywords: GLP-1RA, clinical comprehensive evaluation, health technology assessment, MCDA
1Department of Pharmacy Management, College of International Pharmaceutical Business School, China Pharmaceutical University, Nanjing, People’s Republic of China; 2Department of Pharmacy, School of Pharmaceutical Sciences and Yunnan Provincial Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, People’s Republic of China; 3Health Technology Assessment Research Department, Shanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai, People’s Republic of China
Correspondence: Haiyin Wang, Health Technology Assessment Research Department, Shanghai Health Development Research Center (Shanghai Medical information Center), Shanghai, People’s Republic of China, Email wanghaiyin@shdrc.org
Purpose: GLP-1 receptor agonists have attracted increasing attention due to their dual efficacy in glycemic control and weight reduction. Although several GLP-1 receptor agonists have been included in China’s National Reimbursement Drug List, their actual adoption at the hospital level still faces multiple challenges. A well-structured evaluation framework is urgently needed to facilitate their integration into hospital formularies. This study aims to develop a clinically comprehensive evaluation system for GLP-1 receptor agonists in public hospital drug selection, based on multicriteria decision analysis (MCDA). The goal is to provide a systematic and quantifiable tool to support the rational selection and implementation of GLP-1RAs in public hospitals, thereby enhancing the scientific basis of hospital formulary decisions.
Patients and Methods: The study integrates the Delphi method and multi-criteria decision analysis (MCDA), utilizing literature review, expert consultations, and questionnaire surveys to select and assign weights to evaluation indicators.
Results: A three-tier evaluation system was established, comprising four primary indicators, eight secondary indicators, and seventeen tertiary indicators. Among them, “Clinical Value” had the highest weight (0.5373), followed by “Hospital Admission Demand” (0.1924) and “Hospital Management” (0.1379), while “Economic Value” had the lowest weight (0.1324). At the tertiary level, “Cost-Effectiveness Advantage”, “Glycosylated Hemoglobin”, “Cardiovascular, Hepatic, and Renal Benefits”, “Addressing Unmet Clinical Needs”, and “Hypoglycemia Incidence” contributed most to decision-making.
Conclusion: This study fills the gap in clinical evaluation research on GLP-1RA drugs in China. The proposed evaluation system provides scientific support for hospital pharmaceutical management, medical insurance inclusion, and drug procurement, promoting value-based hospital drug selection strategies.
Keywords: GLP-1RA, clinical comprehensive evaluation, health technology assessment, MCDA